TY - JOUR
T1 - Prognostic impact of positive peritoneal cytology (POPEC) in gastric cancer
T2 - Multi-centre European retrospective cohort study
AU - Owen, Richard
AU - Chidambaram, Swathikan
AU - Shamiyah, Khalid
AU - Elliott, Jessie A.
AU - Hedberg, Jakob
AU - Kamarajah, Sivesh
AU - Klevebro, Frederik
AU - Schneider, Marcel Andre
AU - Fourie, Lana
AU - Gutschow, Christian
AU - Nilsson, Magnus
AU - Griffiths, Ewen
AU - Rosati, Ricardo
AU - Sultan, Javed
AU - Pera, Manuel
AU - Grimminger, Peter
AU - Piessen, Guillaume
AU - Eveno, Clarisse
AU - Ruurda, Jelle
AU - van Hillegersberg, Richard
AU - Reynolds, John V.
AU - van Berge Henegouwen, Mark
AU - Gisbertz, Suzanne
AU - So, Jimmy B.Y.
AU - Maynard, Nick
AU - Markar, Sheraz
AU - Peronace, Vanessa
AU - Boyle, Ellen A.
AU - Pang, Aileen
AU - Yap, Candy
AU - Chia, Daryl
AU - Kim, Guowei
AU - Shabbir, Asim
AU - Youcef, Amina
AU - Bhatti, Khalid
AU - Keywani, Kammy
AU - Calef, Ricardo
AU - Uzun, Eren
AU - Cero, Mariagiulia Dal
AU - Halle-Smith, James
AU - Bagnell, Tim
AU - Triemstra, Lianne
AU - Josef, Matthias
AU - Neuschütz, Kerstin
AU - Cossu, Andrea
AU - Saunders, John
N1 - Publisher Copyright:
© 2025
PY - 2025/9
Y1 - 2025/9
N2 - Objective: Positive peritoneal cytology is traditionally viewed as representative of metastatic disease and a poor prognostic factor. The objective of this multi-center study was to define the prognostic role of peritoneal cytology in curative gastrectomy, evaluate international variation in cytology sampling, and assess the impact on positive peritoneal cytology yields. Methods: This was a multi-center international retrospective cohort study of 16 tertiary gastric cancer centers. Adult patients who underwent peritoneal lavage cytology at staging laparoscopy and subsequent gastrectomy between 2009 and 2023 were included. The primary outcome measure was overall survival at five years. Multivariable Cox regression provided hazard ratios (HRs) with 95 % CIs, adjusted for relevant confounding factors. Results: 837 patients with no radiological or macroscopic M1 disease were included, with a mean age of 66 (IQR 58–73) and 71 % were male. Non-distal gastric cancer was most common (47 %), with 59 % and 43 % of tumors staged pT3/4 and pN2/3, respectively. 66 patients (7.9 %) had positive cytology. Positive cytology was not associated with overall survival in multivariable analysis, controlled for stage and neoadjuvant treatment (HR=1.0; 95 %CI 0.51–2.0). Higher T and N stages were associated with positive cytology (p < 0.001). The proportion of patients with positive cytology was variable, depending on how many quadrants were sampled. Conclusion: Positive peritoneal cytology with otherwise M0 disease was not associated with decreased survival after curative intent gastrectomy in this study, meaning prospective study is needed. The technique of performing peritoneal washings influenced cytology yield and thus must be standardized in a much-needed prospective evaluation of peritoneal cytology. Synopsis: The POPEC multicenter international retrospective cohort study included 837 patients receiving curative gastrectomy. This study showed the technique of performing peritoneal washings influenced cytology yield, however positive peritoneal cytology was not associated with decreased survival. Therefore, positive peritoneal cytology should not be considered an absolute contradiction to curatively intended gastrectomy.
AB - Objective: Positive peritoneal cytology is traditionally viewed as representative of metastatic disease and a poor prognostic factor. The objective of this multi-center study was to define the prognostic role of peritoneal cytology in curative gastrectomy, evaluate international variation in cytology sampling, and assess the impact on positive peritoneal cytology yields. Methods: This was a multi-center international retrospective cohort study of 16 tertiary gastric cancer centers. Adult patients who underwent peritoneal lavage cytology at staging laparoscopy and subsequent gastrectomy between 2009 and 2023 were included. The primary outcome measure was overall survival at five years. Multivariable Cox regression provided hazard ratios (HRs) with 95 % CIs, adjusted for relevant confounding factors. Results: 837 patients with no radiological or macroscopic M1 disease were included, with a mean age of 66 (IQR 58–73) and 71 % were male. Non-distal gastric cancer was most common (47 %), with 59 % and 43 % of tumors staged pT3/4 and pN2/3, respectively. 66 patients (7.9 %) had positive cytology. Positive cytology was not associated with overall survival in multivariable analysis, controlled for stage and neoadjuvant treatment (HR=1.0; 95 %CI 0.51–2.0). Higher T and N stages were associated with positive cytology (p < 0.001). The proportion of patients with positive cytology was variable, depending on how many quadrants were sampled. Conclusion: Positive peritoneal cytology with otherwise M0 disease was not associated with decreased survival after curative intent gastrectomy in this study, meaning prospective study is needed. The technique of performing peritoneal washings influenced cytology yield and thus must be standardized in a much-needed prospective evaluation of peritoneal cytology. Synopsis: The POPEC multicenter international retrospective cohort study included 837 patients receiving curative gastrectomy. This study showed the technique of performing peritoneal washings influenced cytology yield, however positive peritoneal cytology was not associated with decreased survival. Therefore, positive peritoneal cytology should not be considered an absolute contradiction to curatively intended gastrectomy.
KW - Gastric cancer
KW - HIPEC
KW - Hyperthermic Intraperitoneal Chemotherapy
KW - Peritoneal carcinomatosis
KW - Peritoneal cytology
KW - PIPAC
KW - Pressurised IntraPeritoneal Aerosolised Chemotherapy
KW - Surgical oncology
UR - https://www.scopus.com/pages/publications/105010958232
U2 - 10.1016/j.soi.2025.100145
DO - 10.1016/j.soi.2025.100145
M3 - Article
AN - SCOPUS:105010958232
SN - 2950-2470
VL - 2
JO - Surgical Oncology Insight
JF - Surgical Oncology Insight
IS - 3
M1 - 100145
ER -